Socio-economic drivers of drug-resistant tuberculosis in Africa: a scoping review
- PMID: 33706723
- PMCID: PMC7953648
- DOI: 10.1186/s12889-021-10267-0
Socio-economic drivers of drug-resistant tuberculosis in Africa: a scoping review
Abstract
Background: Drug-resistant TB (DR-TB) remains a public health concern due to the high morbidity and mortality rates from the disease. The DR-TB is a multifaceted illness with expensive treatment regimens, toxic medications and most often the long duration of treatment constitutes a substantial financial burden on both infected patients and the health system. Despite significant research advances in the diagnosis and treatment, there is a paucity of synthesized evidence on how socio-economic factors are associated with DR-TB. This review aims to address this gap by synthesizing available evidence and data on the common socio-economic drivers of DR-TB infection in Africa.
Methods: A systematic search was conducted on PUBMED and Google Scholar databases from January 2011 to January 2020 using Joanna Briggs Institute's scoping review approach. An updated search was conducted on 21 September 2020. The eligibility criteria only included systematic reviews and studies with quantitative research methods (cross-sectional, case-control, cohort, and randomized-control trials). Studies conducted in Africa and focusing on socio-economic factors influencing DR-TB burden in African countries were also considered. Data was extracted from all the studies that met the eligibility criteria based on the study's objectives.
Results: Out of the 154 articles that were retrieved for review, 20 abstracts of these articles met all the eligibility criteria. Of the 20 articles, 17 quantitative and 3 reviews. Two additional articles were found eligible, following the updated search. The following themes were identified as major findings: Social and economic drivers associated with DR-TB. Substance abuse of which, stigma and discrimination were the prominent social drivers. Economic drivers included poverty, financial constraints because of job loss, loss of productive time during hospital admission and treatment costs.
Conclusion: This review has highlighted which socio-economic factors contribute to DR- TB This is relevant to assist DR-TB management program and TB stakeholders in different settings to address identified socio-economic gaps and to reduce its negative impact on the programmatic management of DR TB. Therefore, redirecting strategies with more focus on socio-economic empowerment of DR-TB patients could be one of the innovative solutions to reduce the spread and eliminate DR-TB in Africa.
Keywords: Africa; Drug-resistant TB; Socio-economic drivers.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Drug-Resistant Tuberculosis Case-Finding Strategies: Scoping Review.JMIR Public Health Surveill. 2024 Jun 26;10:e46137. doi: 10.2196/46137. JMIR Public Health Surveill. 2024. PMID: 38924777 Free PMC article.
-
High use of private providers for first healthcare seeking by drug-resistant tuberculosis patients: a cross-sectional study in Yangon, Myanmar.BMC Health Serv Res. 2018 Apr 11;18(1):276. doi: 10.1186/s12913-018-3077-y. BMC Health Serv Res. 2018. PMID: 29642905 Free PMC article.
-
Tuberculosis active case-finding interventions and approaches for prisoners in sub-Saharan Africa: a systematic scoping review.BMC Infect Dis. 2020 Aug 5;20(1):570. doi: 10.1186/s12879-020-05283-1. BMC Infect Dis. 2020. PMID: 32758165 Free PMC article.
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis.PLoS One. 2024 Oct 21;19(10):e0309034. doi: 10.1371/journal.pone.0309034. eCollection 2024. PLoS One. 2024. PMID: 39432463 Free PMC article.
-
Case-Finding Strategies for Drug-Resistant Tuberculosis: Protocol for a Scoping Review.JMIR Res Protoc. 2022 Dec 15;11(12):e40009. doi: 10.2196/40009. JMIR Res Protoc. 2022. PMID: 36520530 Free PMC article.
Cited by
-
Treatment of Infection as a Core Strategy to Prevent Rifampicin-Resistant/Multidrug-Resistant Tuberculosis.Pathogens. 2023 May 17;12(5):728. doi: 10.3390/pathogens12050728. Pathogens. 2023. PMID: 37242398 Free PMC article. Review.
-
Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Study of Patients' Characteristics in Selected Healthcare Facilities.Int J Environ Res Public Health. 2024 Nov 30;21(12):1594. doi: 10.3390/ijerph21121594. Int J Environ Res Public Health. 2024. PMID: 39767435 Free PMC article.
-
Drug-Resistant Tuberculosis Stigma Among HealthCare Workers Toward the Development of a Stigma-Reduction Strategy: A Scoping Review.Inquiry. 2023 Jan-Dec;60:469580231180754. doi: 10.1177/00469580231180754. Inquiry. 2023. PMID: 37310064 Free PMC article.
-
Knowledge, attitude and preventative practice of tuberculosis in rural communities of Dikgale, Mamabolo and Mothiba health and demographic surveillance system in Limpopo province, South Africa.BMC Public Health. 2023 Sep 1;23(1):1687. doi: 10.1186/s12889-023-15845-y. BMC Public Health. 2023. PMID: 37658300 Free PMC article.
-
Prevalence and Factors Associated with Substance Use Among Patients with Tuberculosis in Uganda.Res Sq [Preprint]. 2025 Jan 31:rs.3.rs-5927600. doi: 10.21203/rs.3.rs-5927600/v1. Res Sq. 2025. PMID: 39975935 Free PMC article. Preprint.
References
-
- Mcnally TW, De Wildt G, Meza G, Wiskin CMD. Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon–a qualitative study exploring the experiences and perceptions of patients and healthcare professionals. BMC Health Serv Res. 2019;19(1):594. doi: 10.1186/s12913-019-4429-y. - DOI - PMC - PubMed
-
- World Health Organisation . Global tuberculosis report 2018. France: World Health Organization; 2018.
-
- Centre for Disease Prevention and Control . Tuberculosis 2017. Atlanta: US Department of Health and Human Services; 2017.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous